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CORRESPONDENCE
Conserved signatures indicate HIV-1 
transmission is under strong selection and thus 
is not a “stochastic” process
Mileidy Gonzalez1* , Anthony L. DeVico2 and John L. Spouge1
Abstract 
Recently, Oberle et al. published a paper in Retrovirology evaluating the question of whether selection plays a role 
in HIV transmission. The Oberle study found no obvious genotypic or phenotypic differences between donors and 
recipients of epidemiologically linked pairs from the Swiss cohort. Thus, Oberle et al. characterized HIV-1 B transmis-
sion as largely “stochastic”, an imprecise and potentially misleading term. Here, we re-analyzed their data and placed 
them in the context of transmission data for over 20 other human and animal trials. The present study finds that the 
transmitted/founder (T/F) viruses from the Swiss cohort show the same non-random genetic signatures conserved 
in 118 HIV-1, 40 SHIV, and 12 SIV T/F viruses previously published by two independent groups. We provide alternative 
interpretations of the Swiss cohort data and conclude that the sequences of their donor viruses lacked variability at 
the specific sites where other studies were able to demonstrate genotypic selection. Oberle et al. observed no phe-
notypic selection in vitro, so the problem of determining the in vivo phenotypic mechanisms that cause genotypic 
selection in HIV remains open.
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Correspondence
Oberle et al. [1] recently analyzed nine linked HIV-1 sub-
type B transmission pairs from the Zurich Primary HIV 
Infection (ZPHI) study and the Swiss HIV Cohort Study 
(SHCS), generating a novel resource for information 
about HIV donor and recipient viruses. The authors used 
their data to address whether natural HIV transmission 
entails selection for particular phenotypic or genotypic 
characteristics, a question that remains critical to the 
successful development of preventive measures against 
HIV-1 infection. The authors concluded that their data 
favor a model in which HIV-1 transmission is largely “sto-
chastic”. The terminology is in fact misleading, because 
the data are consistent with other evidence confirming 
that selection occurs during viral transmission. Our rea-
soning is described below.
Phenotypic analyses in vitro may not detect genotypic 
selection in vivo
Oberle et  al. examined viruses from donor–recipient 
pairs for certain phenotypic characteristics (e.g., neutrali-
zation and entry inhibitor sensitivity, replicative capac-
ity, sensitivity to Interferon α, etc.). In their cohort, the 
phenotypic traits measured in vitro clearly displayed no 
selection, an interesting and useful finding. The breadth 
of their conclusions about the absence of selection in 
natural HIV transmission is less certain, however. The 
characteristics measured in  vitro, although carefully 
chosen for probable importance in  vivo, may have only 
indirect relevance to the natural transmissibility of HIV. 
Consider, e.g., neutralization sensitivity/resistance, which 
per se (depending on the route of exposure) may have lit-
tle relevance to the rapid establishment of infection in a 
naïve, seronegative host. In summary, the experimental 
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conclusions inevitably hold the caveat that in vitro assays 
may not be able to detect the in vivo selective pressures 
on viral genotypes.
“Stochastic” is an imprecise term when applied to HIV 
transmission
A “stochastic process” is a random function. In the con-
text of HIV transmission, it entails a probability model 
for random variables changing over time. The conclusion 
of “stochastic” transmission therefore only implies some 
degree of randomness, and it does not exclude biological 
selection. If a study concludes that transmission is “sto-
chastic”, therefore, it should probably conclude more 
accurately (and certainly more clearly) that it did not 
detect selection. In fact, a precise statistical framework 
to test for selection asks the question: are T/F viruses 
chosen uniformly at random from the donor pool? The 
null hypothesis for statistical testing is therefore that T/F 
viruses are chosen uniformly at random from the donor 
pool.
Absence of evidence is not evidence of absence
This popular aphorism summarizes our main objection 
with the conclusions of the Oberle study. Absence of 
evidence, or the failure to observe evidence supporting 
a hypothesis in a specific circumstance, is not necessar-
ily broad evidence against the hypothesis. Thus, absence 
of selection (in a specific set of in  vitro tests applied to 
a specific set of donor–recipient pairs) does not consti-
tute evidence against selection and in favor of a uniform 
random process for all subtype B HIV-1 transmissions. 
Selection might even be playing a direct role in the trans-
missions in the Oberle study, but may not be evident per-
haps because of unsuitable data, resolution, algorithms, 
tools, etc. The conclusions of the Oberle study therefore 
need to be appropriately qualified.
Failure to reject the null hypothesis is not the same 
as accepting it
In science, it is standard to calculate p values. When a 
p value is significant, by convention, we reject the null 
hypothesis (e.g., H0 = T/F viruses are chosen uniformly 
at random from the donor pool). Insufficiently signifi-
cant p values, as was the case for the comparisons in the 
Oberle study, are not enough to accept the null hypoth-
esis. Data may simply be too sparse or inappropriate to 
detect weak trends supporting an alternative hypothesis 
(e.g., HA = T/F viruses are under selection).
Signatures in T/F viruses have already demonstrated 
selection during HIV transmission
The authors state: “To what extent HIV-1 transmission 
is a stochastic process or driven by selective forces that 
allow T/F viruses best to overcome bottlenecks in trans-
mission has not been conclusively resolved.” In fact, the 
available literature on this subject consistently shows 
envelope sequence bias during transmission. Gnana-
karan et al. [2] identified one signature in the Env signal 
peptide. We also identified four strong gp120 signatures 
conserved in T/F viruses from twelve different HIV-1, 
SHIV, and SIV trials [3]. Figure  1a illustrates our previ-
ous signature analysis on one of the SIV animal trials. 
The signature scanning algorithm identified that SIV T/F 
viruses were almost invariably Ile[33]-Ala[55]-Lys[57]-
Asn[88] variants, despite I-A-K-N being a minor variant 
in the stock (2%). V-T-R-S constituted the major variant 
in the stock (79%); yet, none of the T/F viruses featured 
those residues at the signature sites (Fig. 1a). While other 
variants can sometimes transmit (e.g., IAKS), they do so 
infrequently and cannot compete in the presence of even 
miniscule proportions of I-A-K-N variants. Our findings 
of selection on T/F viruses were confirmed on data from 
four different vaccine trials by Smith et al. [4].
The A‑[DK]‑N signatures are conserved in HIV‑1, SHIV, 
and SIV T/F Viruses
The extreme diversity of the SIVsmE660 stocks made it 
possible to observe selection at the transmission signa-
ture sites (Fig.  1a). Our previous report demonstrated 
statistical support for the I-A-K-N signatures from three 
different trials challenging vaccinated and unvaccinated 
animals with SIVsmE660O [3–6]. T/F viruses from other 
strains show diversity at site 33; thus, the I33 transmis-
sion signature seems peculiar to SIVsmE660 (Fig. 1b). We 
also showed that the signatures at sites 55, 57, and 88 are 
conserved in T/F viruses from SIVmac251, SHIVBaL, 
and HIV-1 infections (Fig. 1b). The analogous signatures 
in HIV-1 and SHIV are A55-D57-N88. Note that we ana-
lyzed HIV-1 T/F viruses from subtype A [7], subtype B 
(the Step trial [8, 9], the Nairobi breastfeeding trial [10, 
11], and Los Alamos database [2]), subtype C [12], sub-
type D [7], and subtype A1D [7] and SHIV T/F viruses 
from three different sources [3, 13]. For the sake of the 
present analysis, the signature algorithm scanned addi-
tional T/F viruses from one other SHIVBaL vaccine trial 
[14] and 13 infectious molecular T/F clones from the 
NIH AIDS reagents program. All T/F viruses we have 
collected in HIV-1, SHIV, and SIV show the A55-[DK]57-
N88 signature regardless of sex, gender, vaccination sta-
tus, viral dosage, or transmission route (Fig. 1b).
The T/F viruses of the Swiss Cohort also display the same 
conserved transmission signatures reported previously 
in other HIV, SHIV, and SIV T/F viruses
In accordance with the above findings, the signature 
scanning algorithm illustrated in Fig.  1a applied to the 
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genetic data in the Oberle et  al. study reveals that the 
A55, D57, and N88 envelope residues are selectively con-
served in the T/F viruses of the Swiss cohort (Fig.  1c). 
Unfortunately, the diversity and sparsity of donor 
sequences in the Swiss cohort (Fig.  1c) precludes direct 
statistical elucidation of these residues/positions as for-
mal transmission signatures. It is worth mentioning that 
3% of the Swiss donor sequences differ at site 57: i.e., 3% 
of the non-transmitted donor viruses are [EN]57 variants 
whereas all the Swiss T/F viruses are D57 variants. Still, 
since A55-D57-N88 viruses constitute the major variant 
in the Swiss donor and T/F viruses (Fig. 1c) there is not 
enough variation in the Swiss cohort alone to gather sta-
tistical evidence in support of selection. The same cave-
ats make it impossible to draw the opposite conclusion; 
i.e., that there is no selective pressure at these sites during 
transmission  (see above). However, using the observa-
tions of the 170 other T/F viruses (118 HIV-1, 40 SHIV, 
and 12 SIV T/F viruses in Fig. 1b) as a framework, it is 
entirely plausible to interpret A55, D57, and N88 as non-
random markers of T/F viruses in the Swiss cohort.
Conclusions
The Oberle et al. study found no evidence of phenotypic 
or genotypic selection in the transmitted viruses of the 
Swiss cohort; thus, the authors conclude that HIV trans-
mission is largely “stochastic”. Here, we raise the issue 
that the breadth of their conclusions about the absence 
of selection in natural HIV transmission needs to be re-
evaluated. On the one hand, it is well established that 
CCR5 tropism is a phenotypic determinant of HIV trans-




Fig. 1 Transmission signatures conserved in SIV, SHIV, and HIV-1. a An alignment of two sequence logos representing Env sequences from an 
SIVsmE660 stock/inoculum (top) and the T/F (bottom) viruses establishing infections in four animals. The diagram illustrates the signature scanning 
protocol on one SIVsmE660 trial highlighting four signature sites: i.e., sites where the amino acid preference in the donor residue differs significantly 
from that of the T/F based on a Fisher Exact test. See our previous published work for statistical details of signature scanning in 11 other trials [3]. b 
Sequence logos tracking the signature residues in 170 T/F viruses from SIVsmE660, SIVmac251, SHIV-BaL, and HIV-1 (A, B, C, D, A1D). c An alignment 
of the donor (top) and T/F sequences from the study by Oberle et al. Sequence logos were generated using WebLogo software [16, 17]
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[15]. On the other hand, we and others have demon-
strated selection at the genotypic level [3, 4].
It is clear that the viruses in the Swiss cohort alone can-
not provide genotypic evidence of selection due to lim-
ited diversity of donor viral sequences. When considering 
the Swiss cohort sequences in the context of transmis-
sion data from over 20 other studies of human and non-
human primate lentiviruses, we find that the Oberle et al. 
data conform to redundant findings that transmission is 
under strong selection to conserve the A55-[DK]57-N88 
envelope residues.
Relatively limited diversity in donor sequences (in com-
parison to animal donor data) has been typical of every 
human trial thus far, which possibly results from limited 
sampling, shallow sequencing breadth, or from strong 
selection. The latter possibility is supported by findings 
that A55-[DK]57-N88 predominate also in database 
sequences of circulating variants from chronic infec-
tion [3, 4]. The A[DK]N motif seems to predominate in 
circulating HIV-1 and HIV-2 variants. Given the high 
mutation rates and viral turnover in HIV, such levels of 
conservation beyond transmission indicate strong selec-
tion for functional or structural fitness reasons.
Such observations indicate that the A55-[DK]57-
N88 sites are “lethal”; specifically, introducing other 
residues therein extract an extreme fitness cost to the 
virus. What specific role the amino acid residues defin-
ing these putative markers have in increasing HIV trans-
mission efficiency remains unclear. It should be noted 
that the genetic transmission signatures discussed above 
have yet to be directly linked with the phenotypic traits 
Oberle et al. analyzed in their cohort study. Accordingly, 
one interpretation of Oberle et al. is that the key pheno-
typic traits peculiar to HIV-1 T/F variants remain to be 
defined and could benefit from other advanced structural 
analyses, in situ imaging, and/or in vivo analyses of viral 
replication. Taken together, our evidence indicates that 
under phenotypic circumstances not examined in the 
Swiss cohort, HIV T/F viruses are undergoing selection.
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